𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Cetuximab in combination with carboplatin and docetaxel for patients with metastatic or advanced-stage nonsmall cell lung cancer : A multicenter phase 2 study

✍ Scribed by Chandra P. Belani; Marshall T. Schreeder; Ronald G. Steis; Richard A. Guidice; Thomas A. Marsland; Elizabeth H. Butler; Suresh S. Ramalingam

Publisher
John Wiley and Sons
Year
2008
Tongue
English
Weight
91 KB
Volume
113
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

A phase II study of weekly docetaxel plu
A phase II study of weekly docetaxel plus capecitabine for patients with advanced nonsmall cell lung carcinoma
✍ Ji-Youn Han; Dae Ho Lee; Hae Young Kim; Eun Kyung Hong; Sung Min Yoon; Jong Ho C πŸ“‚ Article πŸ“… 2003 πŸ› John Wiley and Sons 🌐 English βš– 86 KB πŸ‘ 1 views

## Abstract ## BACKGROUND Docetaxel is an active agent in advanced nonsmall‐cell lung carcinoma (NSCLC) and demonstrates preclinical and clinical synergism with capecitabine. We conducted the current Phase II study to evaluate the efficacy and safety of the docetaxel/capecitabine combination in ch

Gemcitabine plus oxaliplatin (GEMOX) com
Gemcitabine plus oxaliplatin (GEMOX) combined with cetuximab in patients with progressive advanced stage hepatocellular carcinoma : Results of a multicenter phase 2 study
✍ Amani Asnacios; Laetitia Fartoux; Olivier Romano; Chloe Tesmoingt; Samy Louafi S πŸ“‚ Article πŸ“… 2008 πŸ› John Wiley and Sons 🌐 English βš– 95 KB πŸ‘ 1 views

## Abstract ## BACKGROUND. The authors conducted a phase 2 trial of the antiepidermal growth factor receptor (EGFR) monoclonal antibody cetuximab in combination with the gemcitabine plus oxaliplatin (GEMOX) regimen in patients with documented progressive hepatocellular carcinoma (HCC). ## METHODS